Covington, Davis Polk Lead Eikon's Upsized $381M IPO
law360
4 months ago
41 views
Oncology-focused biopharmaceutical company Eikon Therapeutics began trading publicly Thursday after raising $381 million in its upsized initial public offering.
Continue Reading
Sign up for FREE to read the full article and access 128K+ alternative investment headlines.